Understanding how to improve acceptance of personalized cancer risk information
Official title: Understanding and addressing rejection of personalized cancer risk information
Funded at University of Colorado Denver · NIH-10891606 · Data updated 2026-11-12
This study is all about helping women understand their personal risk for breast cancer so they can make better choices about when to start screening, making sure the information is clear and helpful for everyone.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project start | August 1, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $706,184 |
| NIH project number | 5R01CA279953-02 |
| Project ID | NIH-10891606 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include women aged 40-49 who are considering breast cancer screening and have varying levels of personal risk factors.
✕Less likely to help
Patients who are not eligible for breast cancer screening or those who have already made informed decisions about their screening may not benefit from this research.
What this research studies
This research focuses on enhancing the way personalized cancer risk information is communicated to patients, particularly regarding breast cancer screening. It aims to identify barriers that prevent women from making informed decisions about when to start screening based on their individual risk factors. By utilizing cancer risk prediction models, the study seeks to tailor screening recommendations to maximize benefits and minimize potential harms. The approach includes assessing how well patients comprehend their risk and the implications for their screening choices.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer screening practices that are better tailored to individual risk, ultimately improving patient outcomes.
How similar studies have gone: Previous research has shown that personalized risk communication can improve patient decision-making in cancer screening, indicating a promising approach.
Where this research is happening
-
University of Colorado Denver
Aurora, United States Active
Researchers
- Principal investigator: Scherer, Laura D. — University of Colorado Denver
- Study coordinator: Scherer, Laura D.
Related research
Other NIH-funded projects on the same topics.
-
Injecting immune-boosting medicine into melanoma tumors to help the immune system reject them
This gives an immune-boosting drug directly into melanoma tumors in pet dogs to help their T cells find and destroy the cancer.
-
Immunological mechanisms behind treatment-resistant kidney transplant rejection
This grant explores why certain kidney transplant rejections don’t respond to standard treatments and what immune cells in the graft are driving that resistance.
-
Targeting graft T cells to reduce transplant rejection
A patient-facing study exploring how immune cells within transplanted organs drive rejection and how we might reduce trouble for people who need organ transplants.
-
Engineered kidney 'chip' to study antibody-driven rejection and how the body adapts
A kidney-rejection research grant is developing a miniaturized, human cell–based chip to model how antibodies cause rejection and how kidneys may adapt.
-
Social media, mood, and teens: how the menstrual cycle affects rejection feelings and online experiences
Teenagers using social media may feel stronger negative reactions to online feedback, especially around certain times in their menstrual cycle, which could relate to mood and depression.
-
Understanding how BK virus links infection to kidney transplant rejection
This project looks at how BK polyomavirus reactivation affects kidney transplant patients and aims to use pre-transplant T cell information to tailor immunosuppression and monitoring.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.